Eversept Partners LP lifted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 32.0% during the second quarter, Holdings Channel.com reports. The fund owned 136,397 shares of the biotechnology company’s stock after buying an additional 33,101 shares during the period. Ascendis Pharma A/S accounts for approximately 4.5% of Eversept Partners LP’s holdings, making the stock its 8th largest holding. Eversept Partners LP’s holdings in Ascendis Pharma A/S were worth $15,706,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. LPL Financial LLC increased its position in shares of Ascendis Pharma A/S by 6.2% in the second quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 131 shares during the last quarter. Flinton Capital Management LLC increased its position in shares of Ascendis Pharma A/S by 6.7% in the second quarter. Flinton Capital Management LLC now owns 2,304 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 144 shares during the last quarter. Aperio Group LLC increased its position in shares of Ascendis Pharma A/S by 3.3% in the second quarter. Aperio Group LLC now owns 4,582 shares of the biotechnology company’s stock valued at $528,000 after acquiring an additional 147 shares during the last quarter. Comerica Bank increased its position in shares of Ascendis Pharma A/S by 7.8% in the second quarter. Comerica Bank now owns 2,460 shares of the biotechnology company’s stock valued at $277,000 after acquiring an additional 179 shares during the last quarter. Finally, Meadow Creek Investment Management LLC increased its position in shares of Ascendis Pharma A/S by 6.7% in the second quarter. Meadow Creek Investment Management LLC now owns 3,168 shares of the biotechnology company’s stock valued at $365,000 after acquiring an additional 198 shares during the last quarter.

A number of research firms recently issued reports on ASND. Canaccord Genuity lifted their target price on Ascendis Pharma A/S from $133.00 to $144.00 and gave the company a “buy” rating in a research report on Friday, May 31st. BidaskClub downgraded Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research report on Thursday. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Wedbush reissued a “buy” rating and set a $223.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, June 28th. Finally, Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, August 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $153.29.

NASDAQ ASND traded down $2.22 during trading on Friday, reaching $102.35. 1,285 shares of the company’s stock were exchanged, compared to its average volume of 202,170. The business has a 50 day moving average price of $113.12 and a 200-day moving average price of $115.49. The stock has a market capitalization of $4.44 billion, a P/E ratio of -27.65 and a beta of 0.64. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.59 and a quick ratio of 11.59. Ascendis Pharma A/S has a fifty-two week low of $53.21 and a fifty-two week high of $133.96.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.08). The business had revenue of $3.61 million for the quarter, compared to analyst estimates of $0.68 million. Ascendis Pharma A/S had a negative return on equity of 35.99% and a negative net margin of 932.52%. On average, analysts forecast that Ascendis Pharma A/S will post -5.31 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: What member countries make up the G-20?

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.